Analytical Data
-
Gene name
GAGE2D
- Application
-
Alternative Names
GAGE2D；GAGE8;G antigen 2D
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9UEU5
-
Expression Region
1-116aa
-
AA Sequence
MGSSHHHHHH SSGLVPRGSH MGSMSWRGRS TYRPRPRRYV EPPEMIGPMR PEQFSDEVEP ATPEEGEPAT QRQDPAAAQE GEDEGASAGQ GPKPEADSQE QGHPQTGCEC EDGPDGQEMD PPNPEEVKTP EEGEKQSQC
-
Molecular Weight
15 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
GAGE2D, a member of the GAGE (G antigen) family, has garnered significant attention in cancer research due to its unique expression patterns and potential role in immune response. These proteins are typically found in the germline and are expressed in various tumors but not in most normal tissues, making them promising targets for cancer immunotherapy. The GAGE gene family, which includes several isoforms, is known for encoding cancer/testis (CT) antigens, which can elicit T-cell responses in cancer patients. Recent studies have highlighted that GAGE2D, in particular, may play a role in tumor progression and immune evasion, making it a focal point for developing cancer vaccines and targeted therapies. Understanding the structure and function of GAGE2D, as well as its interaction with the immune system, is essential for harnessing its potential in therapeutic applications. Given the ongoing advancements in understanding its mechanism of action, GAGE2D is poised to be an attractive candidate for further exploration in the context of personalized cancer treatments, particularly in creating more effective and tailored immunotherapeutic strategies.
